Item 7.01 Regulation FD Disclosure.

On January 7, 2022, Immunovant, Inc. issued a press release that it will provide a presentation regarding its business at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by Immunovant, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
Exhibit No.                  Description
99.1                           Press Release, dated January 7, 2022.
                             Cover Page Interactive Data File (embedded within the Inline XBRL
104                          document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses